Research to Practice: Applying the Medical Literature
“Electronic Nicotine-Delivery Systems for Smoking Cessation”
SEPTEMBER |Clinical
A large Swiss study found that e-cigarettes increased smoking cessation, but potential methodological bias & limited long-term safety data make formal recommendations for their use inappropriate.
"Will vaping help me stop smoking?"
SEPTEMBER |Non-Clinical
Vaping might help you quit smoking, but it’s not the safest or best option. Quitting is tough, & your doctor can help. Ask about programs & treatments to make quitting easier.
"Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction"
OCTOBER |
Given finenerone’s limited efficacy & side effect profile, we are unlikely to prescribe finerenone for patients with HFpEF; however, we will be unsurprised to see an increase in patients placed on this medication.
“Tirzepatide for Obesity Treatment & Diabetes Prevention”
NOVEMBER |Clinical
As other GLP-1 receptor agonists are already a part of most primary care practices, the data presented will not fundamentally change our current clinical practice.
"Will tirzepatide help me lose weight & prevent diabetes?"
NOVEMBER |Non-Clinical
If you’re trying to lose weight or prevent diabetes, talk to your primary care doctor. They can help you figure out if tirzepatide is a good fit for you & your health needs.
SEPTEMBER | Clinical
The New England Journal of Medicine
Vaping might help you quit smoking, but it’s not the safest or best option. Quitting is tough, & your doctor can help. Ask about programs & treatments to make quitting easier.
SEPTEMBER| Non-Clinical
The New England Journal of Medicine
Vaping might help you quit smoking, but it’s not the safest or best option. Quitting is tough, & your doctor can help. Ask about programs & treatments to make quitting easier.
OCTOBER
The New England Journal of Medicine
Given finenerone’s limited efficacy and side effect profile, we are unlikely to prescribe finerenone for patients with HFpEF; however, we will be unsurprised to see an increasein patients placed on this medication.
NOVEMBER| Clinical
The New England Journal of Medicine
As other GLP-1 receptor agonists are already a part of most primary care practices, the data presented will not fundamentally change our current clinical practice.
NOVEMBER| Non-Clinical
The New England Journal of Medicine
If you’re trying to lose weight or prevent diabetes, talk to your primary care doctor. They can help you figure out if tirzepatide is a good fit for you & your health needs.
